Alector shares jump as Roche licenses Parkinson's therapy in $1.27 billion deal
Biotechnology dealmaking is continuing in neurodegenerative disease as Alector secures a licensing agreement for its experimental Parkinson's treatment with Roche. The pact includes $100 million upfront and potential milestone payments that bring the total value to as much as $1.27 billion.
Highlights
- Roche's Genentech will pay Alector up to $1.27 billion for exclusive global rights to develop and commercialize AL050 for Parkinson's disease.
- The deal includes a $100 million upfront payment and up to $1.17 billion in milestone payments, plus royalties for Alector.
- Alector shares surged 72% in premarket trading after the deal, reflecting strong investor appetite for late-stage biotech partnerships.
Licensing terms and development responsibilities
As reported by Reuters, Roche's Genentech unit is paying Alector up to $1.27 billion for exclusive worldwide rights to develop, make and sell AL050, an experimental treatment for Parkinson's disease.Genentech is paying $100 million upfront, with up to $1.17 billion more tied to development, regulatory and sales milestones. Alector is also eligible to receive royalties under the agreement.
AL050 is an enzyme replacement therapy designed to address a deficiency of the GCase enzyme, which leads to the buildup of certain fats and a higher risk of Parkinson's disease. Under the deal, Genentech is taking responsibility for development, regulatory submissions, manufacturing and commercialization of the therapy.
Pipeline expansion and market response
The agreement adds to Roche's recent licensing activity as the Swiss drugmaker works to broaden its drug pipeline. In June, Roche agreed a licensing and collaboration deal with Nurix Therapeutics worth up to $2.3 billion for a blood cancer drug.Investors react strongly to the Alector transaction, with the U.S. biotech's shares soaring 72% in premarket trading on Monday. The move highlights the market value attached to late-stage partnering potential and external pipeline building in the biotechnology sector.
In our earlier article on Nvidia’s Groq licensing deal, we covered a Delaware lawsuit challenging how the 2025 transaction was structured, including claims of undervaluation and an effective transfer of key technology and talent via an “acqui-hire” style arrangement. We also noted that U.S. regulators are increasingly scrutinizing such structures for potential attempts to sidestep traditional merger review and antitrust oversight.
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
